Comparison between Revascularization and Optimal Medical Therapy in Patients with Stable Angina Pectoris
Authors
Abstract:
Background and Purpose: Regarding usefulness of revascularization versus optimal medical therapy in patients with stable angina pectoris, data are challenging. The aim of this 12-month follow-up study was to compare the survival benefit associated with revascularization versus optimal medical therapy on the patients with stable angina pectoris. Materials and Methods: A prospective clinical study was conducted on 181 patients with stable angina pectoris or an evidence of myocardial ischemia that underwent coronary arteriography. Patients with left main or left main equivalent were excluded from our study. Of these patients, 57 received full medical therapy alone, 79 were assigned to the percutaneous coronary intervention (PCI) and 45 to the coronary artery bypass graft (CABG) group. The patients were compared for primary outcomes including cardiac death and non-fatal myocardial infarction and secondary outcomes including disabling angina by chi-square and Fisher’s exact test. Results: After 12 months, cardiac death occurred in 8.8% of patients in the medical group and 0.0% of patients in the PCI and CABG group. This was statistically significant (P = 0.004). Disabling angina occurred in 23.1% of patients in the medical group, 17.7% of patients in the PCI group, and 15.5% of patients in CABG group (P = 0.349). Cerebrovascular accident occurred in 1.9% of patients in the medical group, 1.3% of patients in the PCI group, and 6.7% of patients in CABG group (P = 0.167). These were not statistically significant. Conclusion: Revascularization compared with the optimal medical therapy may be a better strategy in reducing cardiovascular mortality in patients with stable angina pectoris and suitable coronary anatomy.
similar resources
comparison between revascularization and optimal medical therapy in patients with stable angina pectoris
background and purpose: regarding usefulness of revascularization versus optimal medical therapy in patients with stable angina pectoris, data are challenging. the aim of this 12-month follow-up study was to compare the survival benefit associated with revascularization versus optimal medical therapy on the patients with stable angina pectoris. materials and methods: a prospective clinical stud...
full textPercutaneous coronary intervention with optimal medical therapy vs. optimal medical therapy alone for patients with stable angina pectoris
SCIENTIFIC BACKGROUND Stable Angina Pectoris (AP) is a main syndrome of chronic coronary artery disease (CAD), a disease with enormous epidemiological and health economic relevance. Medical therapy and percutaneous coronary interventions (PCI) are the most important methods used in the treatment of chronic CAD. RESEARCH QUESTIONS The evaluation addresses questions on medical efficacy, increme...
full textTherapy of Stable Angina Pectoris
Case study: A 62-year-old male smoker with type 2 diabetes mellitus and hypertension presents with a 4-month history of exertional chest pain. Physical examination shows a blood pressure of 152/90 mm Hg but is otherwise unremarkable. The ECG is normal, and laboratory tests show a fasting blood glucose value of 110 mg/dL, glycosylated hemoglobin 6.0%, creatinine 1.1 mg/dL, total cholesterol 160,...
full textEditorial Comment Medical Therapy of Chronic Stable Angina Pectoris
O ur understanding of chronic stable angina is gradually expanding, and two theories have developed in recent years. First, in patients with chronic stable angina, residual coronary flow reserve can be modulated to an important extent by dynamic changes in the caliber of pliable coronary artery stenoses with preserved muscular media.' This theory, coupled with the evidence of the remarkable eff...
full textMedical management of stable angina pectoris.
The number of drugs available for treatment of angina pectoris has increased dramatically in recent years; new beta and calcium channel blockers are to be introduced; nitrates are now available in transdermal pads and could become released as buccal tablets or aerosol sprays. A broad understanding of the pharmacological principles of their use is necessary to tailor therapy for each patient.
full textMy Resources
Journal title
volume 4 issue None
pages 71- 80
publication date 2016-06
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023